ArticleJournal of experimental & clinical cancer research : CR2023

Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.

Magdalena Keller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.